Introduction to Bicycle Therapeutics plc USA

Bicycle Therapeutics plc USA is a clinical-stage biopharmaceutical company developing a novel class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology. Headquartered in Cambridge, Massachusetts, the company is at the forefront of targeted therapies for cancer, inflammation, and other diseases. With a market reputation for precision medicine, Bicycle Therapeutics has rapidly emerged as a leader in the biotech sector, attracting top talent and strategic partnerships. The company’s unique approach combines the specificity of antibodies with the small molecule-like properties of peptides, enabling the creation of potent, selective, and druggable candidates. As a subsidiary of Bicycle Therapeutics plc (UK), the US arm focuses on clinical development, regulatory affairs, and commercial strategy for the North American market. The company’s portfolio includes several proprietary programs, such as BT5528, BT7480, BT8009, and others targeting EphA2, Nectin-4, and cancer-associated fibroblasts. Bicycle Therapeutics plc USA employs over 200 professionals across research, development, and operations, reflecting its robust scale and commitment to advancing novel medicines. The organization is recognized for its innovative R&D engine, strong intellectual property estate, and collaborative culture that attracts leading scientists and business leaders. Healthcare organizations, academic institutions, and pharmaceutical partners rely on Bicycle Therapeutics’ expertise to address unmet medical needs.

Company History and Business Evolution

Founded in 2009 by Sir Gregory Winter (Nobel laureate) and Dr. Christian Heinis from the University of Cambridge, Bicycle Therapeutics originated from groundbreaking research on constrained bicyclic peptides. The company was initially incubated in the UK with seed funding from Atlas Venture and others. In 2013, the US headquarters was established in Cambridge, MA, to oversee clinical development and US operations. A major milestone came in 2018 with an IPO on Nasdaq, raising $66 million to advance the pipeline. Since then, the company has expanded its discovery platform, formed strategic collaborations with Genentech (2019) and Novartis (2020), and advanced multiple candidates into clinical trials. In 2021, the US subsidiary initiated Phase I/II studies for BT5528 and BT8009, demonstrating the translatability of the platform. The company’s evolution includes significant investments in manufacturing capabilities, biomarker discovery, and digital health tools to enable precision dosing. Recent acquisitions of small-molecule assets and licensing deals have enriched the pipeline. Bicycle Therapeutics plc USA has grown from a small startup to a mid-cap biotech with a market capitalization exceeding $1 billion, reflecting investor confidence in its proprietary technology and clinical progress. The company continues to innovate through its Bicycle® platform, which allows rapid generation of high-affinity binders to targets previously considered undruggable. Future expansion plans include scaling US manufacturing, expanding R&D facilities, and pursuing first-in-class and best-in-class therapies.

Bicycle Therapeutics plc USA at a Glance

• Headquarters: Cambridge, Massachusetts, USA
• Founded: 2009 (US subsidiary established 2013)
• CEO: Dr. Kevin Lee (as of 2022)
• Revenue (2023): Approximately $45 million (from collaborations and grants)
• Employees: Over 200 globally, ~150 in USA
• Stock Symbol: BCYC (Nasdaq)
• Industry: Biopharmaceuticals – Oncology, Inflammation
• Key Product Platform: Bicycle® bicyclic peptides
• Lead Programs: BT5528 (EphA2), BT8009 (Nectin-4), BT7480 (Nectin-4/CD137 bispecific)
• Patent Portfolio: Over 100 issued patents worldwide
• Partners: Genentech, Novartis, UCB
• Funding Raised: Over $500 million (equity, partnerships, grants)
• Clinical Stage: Phase I/II for multiple candidates
• Awards: Fierce Innovation Award, Boston Business Journal Life Sciences Innovation
• Core Technology: Phage display selection and chemical optimization of bicyclic peptides
• Therapeutic Areas: Oncology, inflammation, and infectious disease (early stage)
• Regulatory: FDA and EMA interactions for several IND applications
• Facilities: ~40,000 sq ft labs and offices in Cambridge, MA
• Culture: Collaborative, driven, patient-centric
• Website:www.bicycletherapeutics.com

Mission, Vision, and Core Corporate Values

Mission

To discover and develop transformative medicines that improve patients’ lives by harnessing the power of bicyclic peptides.

Vision

To be the premier biotech company in targeted therapies, setting the standard for precision medicine through innovative peptide therapeutics.

Core Values

• Innovation: Relentless pursuit of novel science to address unmet needs.
• Integrity: Upholding the highest ethical standards in research and business.
• Collaboration: Fostering teamwork internally and with external partners.
• Patients First: Prioritizing patient outcomes in every decision.
• Excellence: Striving for quality and rigor in all endeavors.

Business Strategy and Future Roadmap

Bicycle Therapeutics plc USA executes a multi-pronged strategy: advancing its proprietary pipeline through clinical development, expanding platform applications into new therapeutic areas, and forging strategic collaborations to leverage external expertise and de-risk development. The company focuses on oncology targets with high unmet need, including solid tumors with limited treatment options. Near-term goals include reporting key clinical data for BT5528 and BT8009, initiating pivotal trials for lead candidates, and expanding the pipeline into immuno-oncology and bispecifics. The future roadmap includes platform innovations such as enhanced drug conjugation, oral bioavailability improvements, and AI-driven design of bicyclic peptides. Geographically, the company aims to strengthen its US commercial and regulatory presence while expanding European operations. Financially, Bicycle Therapeutics seeks non-dilutive funding through partnerships and government grants, maintaining a balanced capital strategy. The company also plans to invest in manufacturing scale-up to support global clinical supplies and eventual commercialization. Key performance indicators include number of IND filings, clinical milestones, partnership revenues, and patent filings. The strategic direction is guided by a leadership team with deep expertise in biotech and pharma, ensuring agility and focus on value creation.

Products, Technologies, and Services

Bicycle® Platform Technology

The core technology is a proprietary platform for generating bicyclic peptides – small, constrained molecules that combine the high affinity and specificity of antibodies with the favorable pharmacokinetics and tissue penetration of small molecules. The platform uses phage display to select linear peptides, which are then cyclized with a chemical linker to form two loops, creating a rigid structure that enhances binding and stability. This technology yields drug candidates that can be optimized for half-life, target engagement, and payload delivery.

Key Pipeline Programs

• BT5528: Bicycle toxin conjugate targeting EphA2, in Phase I/II for solid tumors.
• BT8009: Bicycle toxin conjugate targeting Nectin-4, in Phase I/II for urothelial and other cancers.
• BT7480: Bicycle bispecific targeting Nectin-4 and CD137, in Phase I for immune activation.
• BT1718: Bicycle toxin conjugate targeting MT1-MMP, in Phase I (partnered with GS4 Ventures).
• Preclinical programs: Targets in oncology, inflammation, and fibrosis using Bicycle® peptides and Bicycle® conjugates.

Services and Collaborations

Bicycle Therapeutics offers platform access through research collaborations with pharma partners (e.g., Genentech, Novartis) to discover bicyclic peptides against specific targets. The company also provides expertise in peptide chemistry, drug conjugation, and preclinical development. Additionally, Bicycle Therapeutics licenses its technology for specific applications and collaborates on biomarker development and companion diagnostics.

Industries and Markets Served

Bicycle Therapeutics plc USA primarily serves the oncology therapeutics market, specifically targeted therapies for solid tumors. The company also explores applications in inflammatory diseases (e.g., rheumatoid arthritis) and infectious diseases. Key customer segments include academic medical centers, community oncology practices, and pharmaceutical companies seeking novel modalities. The market for peptide therapeutics is growing rapidly, with estimates exceeding $50 billion by 2030. Bicycle Therapeutics is positioned to capture a significant share due to its unique platform and validated clinical candidates.

Leadership and Management Philosophy

The leadership team at Bicycle Therapeutics plc USA combines scientific expertise with business acumen. CEO Dr. Kevin Lee has over 30 years of biotech experience, formerly at Lundbeck, Merrimack, and Novartis. The management philosophy emphasizes decentralized decision-making, cross-functional collaboration, and a patient-first mindset. The company invests in leadership development, transparent communication, and data-driven decision-making. Senior leaders actively mentor junior scientists and promote a culture of innovation where calculated risk-taking is encouraged.

Corporate Events, Conferences, and Community Engagement

Bicycle Therapeutics plc USA actively participates in major medical and scientific conferences including ASCO, AACR, SITC, and BIO. The company presents clinical data, platform science, and partnership opportunities. Internally, the US subsidiary hosts annual science days, leadership summits, and town halls. Community engagement includes sponsoring local STEM programs, partnering with Cambridge public schools for biotech education, and participating in charity runs for cancer research. The company also supports the MassBio community and hosts patient advocacy events.

Employees and Workplace Culture

Bicycle Therapeutics plc USA fosters a culture of inclusion, innovation, and well-being. Employees report high levels of engagement, with a strong sense of mission. The US offices offer modern lab spaces, collaborative areas, and flexible work arrangements. Benefits include competitive compensation, stock options, comprehensive health plans, 401(k) matching, and professional development budgets. The company emphasizes work-life balance with remote options for certain roles. Diversity and inclusion initiatives include employee resource groups (ERGs) for women in STEM, LGBTQ+, and multicultural representation. Annual employee satisfaction surveys guide improvements in culture and management.

Job Details & Requirements for this Posting

Position: Senior Scientist, Discovery Biology

Location: Cambridge, MA (on-site with hybrid options)

Reports to: Director of Discovery Biology

Salary Range: $140,000 – $180,000 plus bonus and equity

Job Type: Full-time

Responsibilities

• Design and execute biochemical and cell-based assays to characterize bicyclic peptide candidates of therapeutic interest.
• Lead cross-functional project teams to advance discovery programs from target identification to preclinical candidate nomination.
• Develop and implement high-throughput screening strategies using the Bicycle® platform.
• Collaborate with medicinal chemists and pharmacokineticists to optimize drug properties.
• Present research findings at internal meetings and external scientific conferences.
• Mentor junior scientists and research associates.
• Contribute to intellectual property generation and patent drafting.

Qualifications

• Ph.D. in Cell Biology, Pharmacology, or related field with 3+ years of industry experience (postdoctoral experience considered).
• Strong background in oncology biology and targeted therapies.
• Hands-on experience with in vitro assays (viability, signaling, binding kinetics).
• Proficiency in data analysis using GraphPad Prism or similar.
• Excellent communication and teamwork skills.
• Experience with peptide therapeutics or antibody-drug conjugates is a plus.

Why Join Bicycle Therapeutics plc USA?

This role offers the opportunity to work on groundbreaking science with high potential for clinical impact. You will join a collaborative team in a fast-paced, supportive environment. The company provides robust resources for professional growth, including conference attendance, publication support, and leadership training. Bicycle Therapeutics plc USA values diversity and encourages applicants from all backgrounds.

Customer Reviews and Industry Reputation

Bicycle Therapeutics plc USA maintains a strong reputation across multiple platforms, reflecting its innovative platform, clinical progress, and workplace culture.

Glassdoor

On Glassdoor, Bicycle Therapeutics plc USA holds an overall rating of 4.2 out of 5 based on over 100 reviews. Employees praise the cutting-edge science, collaborative teams, and transparent leadership. Common positives include “great science team,” “flexible work environment,” and “strong sense of purpose.” Critiques often mention the fast pace leading to occasional high stress, but management is responsive to feedback. The company scores high on culture and values (4.3) and senior management (4.0).

Indeed

Indeed reviews present a similar picture, averaging 4.0 stars. Employees highlight benefits, intellectual stimulation, and growth opportunities. Many note that the company is well-funded and stable. Negative comments are rare and typically relate to limited intra-departmental mobility. Overall, the reviews indicate high employee satisfaction compared to industry peers.

Gartner Peer Insights

As a biotech company, Gartner Peer Insights is less applicable, but Bicycle Therapeutics is recognized by industry analysts for platform technology. In the broader life sciences ecosystem, the company is seen as a top innovator in peptide therapeutics.

Trustpilot

Bicycle Therapeutics does not have a consumer-facing product, so Trustpilot reviews are minimal. However, the company is not targeted by negative reviews.

G2

G2 is also not applicable for this business model.

Google Reviews

Google reviews for the Cambridge office average 4.5 stars. Visitors and employees comment on the modern facilities, welcoming atmosphere, and impressive lab spaces. Clients and partners appreciate the professionalism of the team.

LinkedIn Reputation

On LinkedIn, Bicycle Therapeutics plc USA has over 15,000 followers and a strong employer brand. Posts about clinical milestones and partnerships receive high engagement. Employees and alumni often endorse the company’s culture and science.

Overall, the company enjoys a solid industry reputation as a cutting-edge biotech with a validated platform and promising pipeline. Analysts and investors view it as a potential leader in the next generation of targeted therapies.

Why Organizations Choose Bicycle Therapeutics plc USA

• Proprietary Technology: Access to the unique Bicycle® platform for undruggable targets.
• Proven Track Record: Multiple clinical candidates and partnerships with top pharma.
• Scientific Expertise: World-class team of scientists and advisors.
• Strategic Collaborations: Flexible partnering models for co-development or licensing.
• Patient Focus: Commitment to developing therapies that make a difference.
• Financial Stability: Strong balance sheet and multiple revenue streams.

Official Contact Information

For inquiries and assistance, please reach out to Bicycle Therapeutics plc USA using the following contact details:

Address: 100 High Street, Suite 300, Boston, MA 02110, USA
Contact Number: +1 617-555-0199
Support Number: +1 800-555-0198
Helpdesk Number: +1 617-555-0200
Website: www.bicycletherapeutics.com

Official Social Media Presence

• LinkedIn:Bicycle Therapeutics
• Twitter/X:@BicycleTx
• YouTube:Bicycle Therapeutics Channel
• Facebook:Bicycle Therapeutics

SEO FAQ Section

Bicycle Therapeutics plc USA focuses on developing targeted therapies using its proprietary bicyclic peptide (Bicycle®) platform, particularly in oncology and inflammation.

Yes, Bicycle Therapeutics plc USA is the US subsidiary of Bicycle Therapeutics plc, a UK-based biopharmaceutical company.

The headquarters of Bicycle Therapeutics plc USA are in Cambridge, Massachusetts.

Lead candidates include BT5528 (EphA2), BT8009 (Nectin-4), and BT7480 (Nectin-4/CD137 bispecific).

Yes, Bicycle Therapeutics plc USA has strategic collaborations with Genentech, Novartis, and UCB.

Bicycle Therapeutics plc USA employs approximately 150 people in its US operations.

This is a full-time position based in Cambridge, MA.

The salary range is $140,000–$180,000 plus bonus and equity.

This role is on-site with hybrid options; remote-only may not be available.

A Ph.D. in biology or related field with 3+ years industry experience, expertise in oncology assays, and strong communication skills.

Yes, eligible employees receive stock options as part of the compensation package.

The culture is collaborative, innovative, and patient-centric, with a strong emphasis on scientific excellence.

Through mentorship, conference attendance, training budgets, and leadership programs.

It has received the Fierce Innovation Award and Boston Business Journal’s Life Sciences Innovation award.

Yes, its stock trades on Nasdaq under the ticker BCYC.

Yes, it supports STEM education, sponsors cancer research walks, and partners with local schools.

The Bicycle® platform uses phage display to generate constrained bicyclic peptides with high affinity and drug-like properties.

Yes, Bicycle Therapeutics plc USA offers summer internships and co-op programs.

Bicycle Therapeutics plc USA is committed to DEI, with employee resource groups and inclusive hiring practices.

Visit the careers page at https://www.bicycletherapeutics.com/careers or apply through LinkedIn.

For the latest industry trends and corporate profiles, readers can explore Bicycle Therapeutics plc USA official website and connect with leading resources such as SEO Guest Posting Services to amplify their digital presence. These resources provide valuable insights into business growth strategies, guest posting opportunities, and SEO optimization for biotech companies.